发明授权
US08535942B2 Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
有权
可用于HLA-A2阳性患者的磷脂酰肌醇蛋白聚糖-3（GPC3）衍生的肿瘤排斥抗原肽和包含其的药物
- 专利标题： Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
- 专利标题（中）： 可用于HLA-A2阳性患者的磷脂酰肌醇蛋白聚糖-3（GPC3）衍生的肿瘤排斥抗原肽和包含其的药物
-
申请号： US13242019申请日： 2011-09-23
-
公开(公告)号： US08535942B2公开(公告)日： 2013-09-17
- 发明人: Yasuharu Nishimura , Tetsuya Nakatsura , Hiroyuki Komori
- 申请人： Yasuharu Nishimura , Tetsuya Nakatsura , Hiroyuki Komori
- 申请人地址： JP Kanagawa
- 专利权人： Oncotherapy Science, Inc.
- 当前专利权人： Oncotherapy Science, Inc.
- 当前专利权人地址： JP Kanagawa
- 代理机构： Greenblum & Bernstein, P.L.C.
- 优先权： JP2005-230702 20050809
- 主分类号： C12N5/00
- IPC分类号： C12N5/00 ; C12N5/02 ; C12N5/08 ; A61K39/38 ; A61K39/385
摘要：
It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.